| Literature DB >> 29914800 |
Natalie I Mazur1, Deborah Higgins2, Marta C Nunes3, José A Melero4, Annefleur C Langedijk5, Nicole Horsley6, Ursula J Buchholz7, Peter J Openshaw8, Jason S McLellan9, Janet A Englund10, Asuncion Mejias11, Ruth A Karron12, Eric Af Simões13, Ivana Knezevic14, Octavio Ramilo15, Pedro A Piedra16, Helen Y Chu17, Ann R Falsey18, Harish Nair19, Leyla Kragten-Tabatabaie20, Anne Greenough21, Eugenio Baraldi22, Nikolaos G Papadopoulos23, Johan Vekemans24, Fernando P Polack25, Mair Powell26, Ashish Satav27, Edward E Walsh28, Renato T Stein29, Barney S Graham30, Louis J Bont31.
Abstract
The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29914800 DOI： 10.1016/S1473-3099(18)30292-5
Source DB: PubMed Journal: Lancet Infect Dis ISSN： 1473-3099 Impact factor: 25.071